Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils.

[1]  K. Hamann,et al.  Augmentation of stimulated eosinophil degranulation by VLA-4 (CD49d)-mediated adhesion to fibronectin. , 1994, American journal of respiratory cell and molecular biology.

[2]  L. Lichtenstein,et al.  Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. , 1994, The Journal of allergy and clinical immunology.

[3]  L. Lichtenstein,et al.  GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. , 1993, Journal of immunology.

[4]  R. Braun,et al.  Increased expression of CD11b and functional changes in eosinophils after migration across endothelial cell monolayers. , 1993, Journal of immunology.

[5]  W. Busse,et al.  IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. , 1993, The American review of respiratory disease.

[6]  J. Lammers,et al.  Cytokine priming of the respiratory burst in human eosinophils is Ca2+ independent and accompanied by induction of tyrosine kinase activity , 1993, Journal of leukocyte biology.

[7]  A. Wardlaw,et al.  Adhesion to fibronectin prolongs eosinophil survival , 1993, The Journal of experimental medicine.

[8]  S. Durham,et al.  Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. , 1993, American journal of respiratory cell and molecular biology.

[9]  W. Busse,et al.  Comparison of airway and blood eosinophil function after in vivo antigen challenge. , 1992, Journal of immunology.

[10]  C. Kortsik,et al.  Cytokines, platelet activating factor and eosinophils in asthma. , 1992, Respiratory medicine.

[11]  H. Kita,et al.  Release of granule proteins from eosinophils cultured with IL-5. , 1992, Journal of immunology.

[12]  T. Fukuda,et al.  Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. , 1992, The American review of respiratory disease.

[13]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[14]  B. Vargaftig,et al.  Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists. , 1991, Journal of immunology.

[15]  P. Dri,et al.  Eosinophil activation on biologic surfaces. Production of O2- in response to physiologic soluble stimuli is differentially modulated by extracellular matrix components and endothelial cells. , 1991, Journal of immunology.

[16]  W. Owen,et al.  Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP. , 1991, The Journal of clinical investigation.

[17]  C. Wegner,et al.  Inflammation and cell-cell interactions in airway hyperresponsiveness. , 1991, The American journal of physiology.

[18]  G. Gleich.  The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[19]  H. Kita,et al.  Regulatory effect of cytokines on eosinophil degranulation. , 1990, Journal of immunology.

[20]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[21]  W. Busse,et al.  The appearance of hypodense eosinophils in antigen-dependent late phase asthma. , 1989, The American review of respiratory disease.

[22]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[23]  W. Busse,et al.  Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. , 1988, The Journal of allergy and clinical immunology.

[24]  A. Wardlaw,et al.  The role of the eosinophil in the pathogenesis of asthma , 1987, Allergy.

[25]  W. Owen,et al.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts , 1987, The Journal of experimental medicine.

[26]  J. Dipersio,et al.  Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. , 1986, Journal of immunology.